Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) as Induction Therapy and a Randomized Trial of Thalidomide vs Thalidomide Plus Oral Idarubicin as Maintenance Therapy in Patients With Multiple Myeloma.
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Idarubicin (Primary) ; Thalidomide (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Feb 2010 Planned end date changed from 1 Dec 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 24 Mar 2009 Lead trial investigator (Schmidt-Wolf I) identified as reported by ClinicalTrials.gov.
- 17 Nov 2005 New trial record.